Christopher L. Herold

566 total citations
13 papers, 460 citations indexed

About

Christopher L. Herold is a scholar working on Molecular Biology, Surgery and Pharmacology. According to data from OpenAlex, Christopher L. Herold has authored 13 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Surgery and 5 papers in Pharmacology. Recurrent topics in Christopher L. Herold's work include Cardiovascular, Neuropeptides, and Oxidative Stress Research (5 papers), Apelin-related biomedical research (5 papers) and Adenosine and Purinergic Signaling (3 papers). Christopher L. Herold is often cited by papers focused on Cardiovascular, Neuropeptides, and Oxidative Stress Research (5 papers), Apelin-related biomedical research (5 papers) and Adenosine and Purinergic Signaling (3 papers). Christopher L. Herold collaborates with scholars based in United States, United Kingdom and Germany. Christopher L. Herold's co-authors include Robert A. Nicholas, Stephen A. Douglas, Nambi Aiyar, Charles Kennedy, T K Harden, David J. Behm, T. Kendall Harden, Zhaohui Ao, Diane P. Naselsky and Kristeen Maniscalco and has published in prestigious journals such as Journal of Biological Chemistry, Biochemical and Biophysical Research Communications and Journal of Hepatology.

In The Last Decade

Christopher L. Herold

12 papers receiving 452 citations

Peers

Christopher L. Herold

SURGE

PHARM

CCM

PHYSI

Weijian Shao United States

Loreto Carrasco Chile

Corinna Dickel Germany

Diane P. Naselsky United States

Ana Crane United States

Alexandre Murza Canada

Charlotte Kane United Kingdom

Catharina van Heusden United States

Cristina Solà-Adell Spain

John E. Cuffe United Kingdom

Weijian Shao United States

Christopher L. Herold

45 ×0.2

SURGE

44 ×0.2

PHARM

252 ×1.6

CCM

204 ×1.4

14 ×0.1

PHYSI

Citations per year, relative to Christopher L. Herold Christopher L. Herold (= 1×) peers Weijian Shao

Countries citing papers authored by Christopher L. Herold

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Herold more than expected).

Fields of papers citing papers by Christopher L. Herold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Herold. The network helps show where Christopher L. Herold may publish in the future.

Co-authorship network of co-authors of Christopher L. Herold

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Herold. A scholar is included among the top collaborators of Christopher L. Herold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Herold. Christopher L. Herold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Gahr, Susanne, et al.. (2008). Der Histon-Deacetylasehemmer MS-275 und der CDK-Inhibitor CYC-202 fördern antitumorale Effekte in Hepatomzelllinien. Zeitschrift für Gastroenterologie. 46(9).

Ganslmayer, Marion, et al.. (2005). The Histone-Deacetylase Inhibitor SAHA Potentiates Pro-Apoptotic Effects of 5-Fluorouracil and Irinotecan in Hepatoma Cells. Zeitschrift für Gastroenterologie. 43(1). 6 indexed citations

Douglas, Stephen A., Diane P. Naselsky, Zhaohui Ao, et al.. (2004). Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines. British Journal of Pharmacology. 142(6). 921–932. 32 indexed citations

Herold, Christopher L., et al.. (2004). Agonist Versus Antagonist Action of ATP at the P2Y4 Receptor Is Determined by the Second Extracellular Loop. Journal of Biological Chemistry. 279(12). 11456–11464. 41 indexed citations

Behm, David J., Christopher L. Herold, Valeria Camarda, Nambi Aiyar, & Stephen A. Douglas. (2004). Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. European Journal of Pharmacology. 492(2-3). 113–116. 20 indexed citations

Johns, Douglas G., Zhaohui Ao, Diane P. Naselsky, et al.. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn-Schmiedeberg s Archives of Pharmacology. 370(4). 238–250. 92 indexed citations

Herold, Christopher L., David J. Behm, Peter T. Buckley, et al.. (2003). The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors. British Journal of Pharmacology. 139(2). 203–207. 43 indexed citations

Herold, Christopher L., Marion Ganslmayer, Matthias Ocker, et al.. (2003). Overadditive anti-tumoral effect of a combination of a histone deacetylase — and an angiogenesis inhibitor acts in rat hepatocellular carcinoma in vivo. Journal of Hepatology. 38. 19–19. 1 indexed citations

Behm, David J., Christopher L. Herold, Eliot H. Ohlstein, et al.. (2002). Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist. British Journal of Pharmacology. 137(4). 449–458. 42 indexed citations

10.

Kennedy, Charles, et al.. (2000). ATP, an Agonist at the Rat P2Y4 Receptor, Is an Antagonist at the Human P2Y4 Receptor. Molecular Pharmacology. 57(5). 926–931. 97 indexed citations

11.

Herold, Christopher L., Qing Li, Joel B. Schachter, T. Kendall Harden, & Robert A. Nicholas. (1997). Lack of Nucleotide-Promoted Second Messenger Signaling Responses in 1321N1 Cells Expressing the Proposed P2Y Receptor, p2y7. Biochemical and Biophysical Research Communications. 235(3). 717–721. 34 indexed citations

12.

Herzyk, Danuta J., et al.. (1997). Single-Organism Model of Host Defense against Infection: A Novel Immunotoxicologic Approach to Evaluate Immunomodulatory Drugs. Toxicologic Pathology. 25(4). 351–362. 14 indexed citations

13.

Ichiki, Toshihiro, Christopher L. Herold, Yoshikazu Kambayashi, S. Bardhan, & Tadashi Inagami. (1994). Cloning of the cDNA and the genomic DNA of the mouse angiotensin II type 2 receptor. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1189(2). 247–250. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact